🔗 Share this article World Health Organization Raises Alert Over Critical Lack of Obesity Injections Less than a tenth of individuals who could benefit from weight-loss injections such as Wegovy have access to them, states the World Health Organization as it publishes its inaugural guidance on the drugs. Given more than one billion people worldwide now living with obesity, it is advocating for broader and more equitable availability to these injectable treatments. Per forecasts, over two billion could be obese by 2030 if no action is taken. "The latest guidance recognises that obesity is a long-term condition that can be managed with comprehensive and ongoing care," stated the agency's head Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and distribution challenges are significant obstacles to broad availability to the jabs that can help people shift significant body mass, notes the agency. Skinny Jab Shortage Even under the present most favorable case, the supply of these medications might only reach around 100 million people – fewer than 10% of eligible patients, as stated by the WHO. The advice calls on nations and manufacturers to expand access, by measures like patent sharing. Exclusive production rights on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple nations in 2026. The Way Obesity Injections Operate GLP-1 drugs imitate a natural hormone to slow digestion, curb appetite and increase satiety so users reduce food intake. People typically start to lose weight within a few weeks of commencing the weekly injections. Studies suggests patients may see weight return a year later of stopping the drug, when their typical food cravings resume. Being overweight or obese elevates your chance for experiencing diseases, such as diabetes, heart disease, brain attack, and some malignancies. Excess weight impacts individuals in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, according to the health agency.
Less than a tenth of individuals who could benefit from weight-loss injections such as Wegovy have access to them, states the World Health Organization as it publishes its inaugural guidance on the drugs. Given more than one billion people worldwide now living with obesity, it is advocating for broader and more equitable availability to these injectable treatments. Per forecasts, over two billion could be obese by 2030 if no action is taken. "The latest guidance recognises that obesity is a long-term condition that can be managed with comprehensive and ongoing care," stated the agency's head Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and distribution challenges are significant obstacles to broad availability to the jabs that can help people shift significant body mass, notes the agency. Skinny Jab Shortage Even under the present most favorable case, the supply of these medications might only reach around 100 million people – fewer than 10% of eligible patients, as stated by the WHO. The advice calls on nations and manufacturers to expand access, by measures like patent sharing. Exclusive production rights on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple nations in 2026. The Way Obesity Injections Operate GLP-1 drugs imitate a natural hormone to slow digestion, curb appetite and increase satiety so users reduce food intake. People typically start to lose weight within a few weeks of commencing the weekly injections. Studies suggests patients may see weight return a year later of stopping the drug, when their typical food cravings resume. Being overweight or obese elevates your chance for experiencing diseases, such as diabetes, heart disease, brain attack, and some malignancies. Excess weight impacts individuals in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, according to the health agency.